ArticleBMJ open2017
What is the impact of giant cell arteritis on patients' lives? A UK qualitative study.
Article in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.Arthritis research & therapy · 2019Trial
- Patient-reported outcomes and disease activity in giant cell arteritis: a longitudinal registry-based study.Rheumatology (Oxford, England) · 2026Article
- Measurement of the impact of giant cell arteritis and treatment with glucocorticoids on health-related quality of life.Therapeutic advances in musculoskeletal disease · 2026Review
- Understanding the patient experience of newly diagnosed giant cell arteritis.Rheumatology advances in practice · 2026Article
- Patient perspectives on life impact and unmet needs in giant cell arteritis and polymyalgia rheumatica: insights from social media.Rheumatology advances in practice · 2026Article
- Illness Burden and Unmet Patient Needs in Giant Cell Arteritis: Current State and Future Prospects.Open access rheumatology : research and reviews · 2025Review
- Social determinants of health influence patients' access to care for vasculitis.Clinical rheumatology · 2024Article
- Anxiety and depression in patients with giant cell arteritis.Rheumatology advances in practice · 2024Article
- Fatigue: It Is Not Always in the Head.Cureus · 2023Article
- Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis.Frontiers in medicine · 2023Article
- Patterns of attendances to the hospital emergency eye care service: a multicentre study in England.Eye (London, England) · 2022Article
- Comment on: Benchmarking tocilizumab use for giant cell arteritis.Rheumatology advances in practice · 2022Article
- Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure.Rheumatology (Oxford, England) · 2021Article
- Vasculitis patient journey: a scoping review of patient experiences with vasculitis.Clinical rheumatology · 2021Article
- Patient Reported Outcomes in Large Vessel Vasculitides.Current rheumatology reports · 2021Review
- Impact of Giant Cell Arteritis and Its Treatment on the Patient's Quality of Life: A Single-Center Self-Assessment Study.Frontiers in medicine · 2021Article
- Morbidity and Mortality of Large-Vessel Vasculitides.Current rheumatology reports · 2020Review
- Characteristics of patients with giant cell arteritis who experience visual symptoms.Rheumatology international · 2019Article
- Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes.Patient related outcome measures · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesClinical management of giant cell arteritis (GCA) involves balancing the risks and burdens arising from the disease with those arising from treatment, but there is little research on the nature of those burdens. We aimed to explore the impact of giant cell arteritis (GCA) and its treatment on patients' lives.
methodsUK patients with GCA participated in semi-structured telephone interviews. Inductive thematic analysis was employed.
results24 participants were recruited (age: 65-92 years, time since diagnosis: 2 months to >6 years). The overarching themes from analysis were: ongoing symptoms of the disease and its treatment; and 'life-changing' impacts. The overall impact of GCA on patients' lives arose from a changing combination of symptoms, side effects, adaptations to everyday life and impacts on sense of normality. Important factors contributing to loss of normality were glucocorticoid-related treatment burdens and fear about possible future loss of vision.
conclusionsThe impact of GCA in patients' everyday lives can be substantial, multifaceted and ongoing despite apparent control of disease activity. The findings of this study will help doctors better understand patient priorities, legitimise patients' experiences of GCA and work with patients to set realistic treatment goals and plan adaptations to their everyday lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.